Axol Bioscience acquires Phenocell to advance human disease models

Acquisition expands Axol’s iPSC-derived cell models and service offering to include ophthalmology and dermatology

30-Oct-2024
Computer-generated image

Symbolic image

Axol Bioscience Ltd. (Axol), a induced pluripotent stem cell (iPSC) technology provider for drug discovery, announced it has fully acquired Phenocell SAS, a pioneer in iPSC-based products and bioassays for skin and retinal disorders.

The acquisition extends Axol’s portfolio of iPSC-derived cell models, adding skin and human retinal iPSC-derived cell lines to its existing neuroscience, pain and touch, and cardiovascular products and services. Phenocell’s offering includes market-leading human iPSC-derived sebocytes and retinal pigment epithelium (RPE) and photoreceptor cells. Additionally, the company provides custom, skin and dry age-related macular degeneration (AMD) services to support drug discovery companies.

Financial terms of the agreement are not disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

Under the magnifying glass: The world of microscopy